



Case Study - Gynaecology

Veeda are currently performing a series of studies, single and multiple ascending doses and Phase IIa, for a drug intended to reduce the size of fibroids. A full range of tests is required for these studies including transvaginal and abdominal ultrasound for both uterine morphology and uterine blood flow as well as ovarian blood flow. In the Phase IIa part of the study, the size uterine fibroids will be regularly measured in order to assess the rate and degree of shrinkage.

A wide range of biomarkers are employed in this study to identify unintended effects of the drug on ovarian function – which might be anticipated from its class.

One of the most notable requirements of this study is the necessity to recruit some 40% Afro-Caribbean volunteers. This is required because this population has a high incidence of uterine fibroids even at a young age.